{"url_path":"/sec/mreo/8-k/2026-08-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","accession_number":"0001193125-26-343519","cik":"0001719714","ticker":"MREO","issuer_name":"Mereo BioPharma Group plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1719714/0001193125-26-343519-index.html","primary_entity_key":"0001719714","primary_entity_name":"Mereo BioPharma Group plc"},"word_count":339,"has_tables":true,"body_markdown":"8-K\n\n0001719714trueFalseX000-00000000001719714dei:AdrMember2026-08-112026-08-1100017197142026-08-112026-08-110001719714us-gaap:CommonStockMember2026-08-112026-08-11\n\n \n\n \n\nUNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n \n\nFORM 8-K\n\n \n\nCurrent Report\n\nPursuant to Section 13 or 15(d) of\n\nthe Securities Exchange Act of 1934\n\n \n\nDate of Report (Date of earliest event reported): August 11, 2026\n\n \n\nMEREO BIOPHARMA GROUP PLC\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n\n \n\n \n\n \n\n \n\nEngland and Wales\n\n \n\n001-38452\n\n \n\nNot Applicable\n\n(State or other jurisdiction of\nincorporation)\n\n \n\n(Commission File Number)\n\n \n\n(IRS Employer Identification No.)\n\n \n\n4th Floor, One Cavendish Place,\n\nLondon, W1G 0QF\n\nUnited Kingdom\n\n(Address of principal executive offices, including zip code)\n\n \n\n+44-333-023-7300\n\n(Registrant’s telephone number, including area code)\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\n \n\nTrading Symbol\n\n \n\nName of each exchange on which\nregistered\n\nAmerican Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share\n\n \n\nMREO\n\n \n\nThe Nasdaq Stock Market LLC\n\nOrdinary Shares, nominal value £0.003 per share*\n\n \n\n*\n\n \n\nThe Nasdaq Stock Market LLC\n\n*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}